Qilian International Holding Group Limited logo

Qilian International Holding Group Limited(BGM)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.54
10/30/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BGM

10/30/2026: BGM (1-star) is currently NOT-A-BUY. Pass it for now.

Qilian International Holding Group Limited is a small-cap firm operating in China's pharmaceutical and agricultural chemical markets. While the company has built a niche presence through its manufacturing of APIs, TCM products, and fertilizers, it remains a smaller player compared to regional conglomerates. Its main growth opportunity lies in leveraging its specialized production capabilities, but success is heavily dependent on navigating China's complex regulatory landscape. Risks include high price volatility, intense competition from better-funded peers, and a lack of liquidity. This stock is best suited for speculative investors familiar with the risks of small-cap, international equities; stakeholders should monitor regulatory updates and production efficiency improvements.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe company's limited scale and regional focus offer modest growth potential relative to larger industry peers.
Momentum investorWeak fitThe stock lacks the high trading volume and consistent upward price trend required for momentum strategies.
Value investorMixed fitPotential value may exist if the stock trades below book value, but business quality remains a significant concern.
Dividend investorWeak fitThe company does not provide reliable dividend income, making it unsuitable for income-focused portfolios.
Low-risk investorWeak fitSmall-cap, international, and sector-specific risks make this a high-volatility investment.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to significant price swings due to low liquidity and small market capitalization.
Valuation riskMedium / highAccurately valuing small-cap, foreign-listed companies is difficult due to information asymmetry and market sentiment.
Competition risk (Pharmaceutical/Fertilizer)HighThe company competes with much larger, better-funded domestic firms in both its pharma and chemical segments.
Business qualityMediumThe business relies on a limited product set and regional market dominance which may lack durability.
Dividend incomeLow / noneThere is no current expectation of dividend distributions, negating income utility.
Execution riskMedium / highOperational success is tied to navigating complex and evolving regulatory environments in China.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -53.88%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 10/30/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BGM receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BGM has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, strong revenue growth (+51.1%) is partially offset by negative earnings growth (-1282.1%), weak cash generation (FCF margin -11.7%), weak profitability (net margin -52.6%).

Financial Health Rating

★★★★★
BGM's financial health is soft, with the relatively strongest area being soft efficiency, including operating-expense and cost-of-revenue discipline (opex 46.0% of revenue). Profitability is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is BGM's strongest growth driver at +51.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-1282.1%, negative) and free-cash-flow growth (-31.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.1% (soft) and 36.5% of outstanding shares are publicly tradable (moderate). Insider ownership of 38.05% supports management-shareholder alignment.

Top 5 Institutional Investors

Geode Capital Management, LLC 0.02%
XTX Topco Ltd 0.02%
UBS Group AG 0.01%
Jane Street Group LLC 0.01%
Virtu Financial LLC 0.01%

Unit Economics (Per $1K Revenue)

★★★★★
BGM generates approximately $128 of gross profit, $-332 of operating income, and $-117 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.39% (Tax Credit)

Quantitative Style Profile

★★★★★
BGM has a Value-Oriented profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 127.40M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 21.1K shares
Beta 1.46
52 Weeks Range 6.45 - 302.40
Updated Date 11/01/2026
52 Weeks Range 6.45 - 302.40
Updated Date 11/01/2026
Dividends yield (FY) -
Basic EPS (TTM) -4.8

How Company Makes Money

Business areaWhat it includesRetail investor read
Pharmaceutical ProductsAnti-viral and antibiotic ingredients and medications.This is a core revenue driver but faces intense competition from larger Chinese pharmaceutical players.
Traditional Chinese MedicineHerbal-based supplements and therapeutics.This segment leverages local resources but depends heavily on consumer preferences and health trends.
Chemical FertilizersIndustrial-grade fertilizers for regional agricultural use.A legacy business segment that provides steady but low-margin revenue based on regional demand.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 116.94M
Price to Sales(TTM) 2.66
Enterprise Value 116.94M
Price to Sales(TTM) 2.66
Enterprise Value to Revenue 2.44
Enterprise Value to EBITDA -2.48
Shares Outstanding 12.69M
Shares Floating 4.63M
Shares Outstanding 12.69M
Shares Floating 4.63M
Percent Insiders 38.05
Percent Institutions 0.1

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.